Network meta-analysis of 6 trials (2500 patients) of chemotherapy-free anti-CD20 combinations in relapsed/refractory follicular lymphoma: epcoritamab plus R2 ranked highest for OS, PFS and response, with tafasitamab plus R2 second and better safety.
Meta-analysisn = 2,500
Caracciolo et al. Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis